Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Oncobiologics (ONS) Competitors

Oncobiologics logo

ONS vs. PRME, JATT, PLX, IKT, IZTC, ZIVO, CRTX, ALVR, CVM, and FNCH

Should you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Prime Medicine (PRME), JATT Acquisition (JATT), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), ZIVO Bioscience (ZIVO), Cortexyme (CRTX), AlloVir (ALVR), CEL-SCI (CVM), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector.

Oncobiologics vs. Its Competitors

Oncobiologics (NASDAQ:ONS) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Prime Medicine had 6 more articles in the media than Oncobiologics. MarketBeat recorded 6 mentions for Prime Medicine and 0 mentions for Oncobiologics. Prime Medicine's average media sentiment score of 0.13 beat Oncobiologics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.

Company Overall Sentiment
Oncobiologics Neutral
Prime Medicine Neutral

Oncobiologics has a beta of -0.27, indicating that its share price is 127% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500.

Prime Medicine has a net margin of 0.00% compared to Oncobiologics' net margin of -464.47%. Oncobiologics' return on equity of 0.00% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Oncobiologics-464.47% N/A -93.28%
Prime Medicine N/A -107.87%-74.97%

Oncobiologics has higher earnings, but lower revenue than Prime Medicine.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncobiologics$3.81M37.14-$38.84MN/AN/A
Prime Medicine$4.96M93.80-$198.13M-$1.56-2.22

7.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 11.5% of Oncobiologics shares are owned by insiders. Comparatively, 22.7% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Prime Medicine has a consensus target price of $8.92, indicating a potential upside of 157.71%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than Oncobiologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Prime Medicine
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75

Summary

Prime Medicine beats Oncobiologics on 13 of the 15 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONS vs. The Competition

MetricOncobiologicsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ Exchange
Market Cap$141.51M$281.67M$5.49B$9.70B
Dividend YieldN/AN/A4.64%4.13%
P/E RatioN/AN/A21.9224.75
Price / Sales37.14563.47448.79103.89
Price / CashN/A22.4437.7258.50
Price / Book-1.449.118.306.01
Net Income-$38.84M-$115.81M$3.26B$265.10M

Oncobiologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONS
Oncobiologics
N/A$1.96
+3.2%
N/A-74.1%$141.51M$3.81M0.00N/AGap Up
High Trading Volume
PRME
Prime Medicine
3.6475 of 5 stars
$3.79
+3.0%
$8.92
+135.3%
-16.3%$509.74M$3.85M-1.85234Gap Up
JATT
JATT Acquisition
N/A$1.42
-4.1%
N/A-58.1%$140.76MN/A0.003Gap Up
High Trading Volume
PLX
Protalix BioTherapeutics
2.8617 of 5 stars
$1.54
+2.0%
$15.00
+874.0%
+54.8%$122.60M$59.76M-11.85200Insider Trade
IKT
Inhibikase Therapeutics
1.9354 of 5 stars
$1.43
-7.7%
$6.50
+354.5%
+18.0%$106.31MN/A-0.546
IZTC
Invizyne Technologies
N/A$9.84
-1.7%
N/AN/A$61.52MN/A0.0029Gap Down
ZIVO
ZIVO Bioscience
0.0693 of 5 stars
$14.49
flat
N/A+80.1%$55.31M$15.85K-2.9710
CRTX
Cortexyme
N/A$1.65
-1.2%
N/A+139.1%$49.75MN/A-0.5655
ALVR
AlloVir
N/A$2.67
-1.5%
N/A-84.0%$49.48MN/A-0.13110
CVM
CEL-SCI
0.2644 of 5 stars
$7.44
-9.6%
N/A-80.8%$39.59MN/A-15.5043
FNCH
Finch Therapeutics Group
N/A$12.45
flat
N/A+201.4%$19.99MN/A-1.41190

Related Companies and Tools


This page (NASDAQ:ONS) was last updated on 8/12/2025 by MarketBeat.com Staff
From Our Partners